NCT04684446 - Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

November 26, 2021

Study Completion Date

March 29, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

AZD1222

Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study

BIOLOGICAL

rAd26-S

Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29

Trial Locations (4)

115419

OJSC Clinical and Diagnostic Center Euromedservice, Moscow

196158

LLC PiterClinica, Saint Petersburg

197022

"Federal State Budgetary Educational Institution of Higher Education First Saint Petersburg State Medical University named after Academician I. P. Pavlov of the Ministry of Healthcare of the Russian Federation", Saint Petersburg

197376

"Federal State Budget Institution Scientific and Research Institute of Flu n.a. A.A. Smorodintseva of Ministry of Health of Russian Federation", Saint Petersburg